Boyer Jennifer Yi Sells 10,770 Shares of Inogen (NASDAQ:INGN) Stock

Inogen, Inc (NASDAQ:INGN) EVP Boyer Jennifer Yi sold 10,770 shares of Inogen stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $6.53, for a total transaction of $70,328.10. Following the completion of the sale, the executive vice president owned 15,977 shares of the company’s stock, valued at $104,329.81. This trade represents a 40.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Inogen Stock Performance

INGN opened at $5.98 on Thursday. The firm has a market cap of $161.94 million, a P/E ratio of -6.57 and a beta of 1.60. Inogen, Inc has a 52-week low of $5.34 and a 52-week high of $9.13. The business’s fifty day moving average is $6.59 and its 200-day moving average is $6.48.

Inogen (NASDAQ:INGN) last released its earnings results on Thursday, May 7th. The medical technology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.06). The company had revenue of $85.11 million for the quarter, compared to analyst estimates of $82.35 million. Inogen had a negative return on equity of 12.90% and a negative net margin of 7.08%. On average, research analysts predict that Inogen, Inc will post -0.77 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. CSM Advisors LLC bought a new position in shares of Inogen in the 3rd quarter valued at $2,973,000. GSA Capital Partners LLP bought a new position in shares of Inogen in the 3rd quarter valued at $1,397,000. AlphaQuest LLC lifted its stake in shares of Inogen by 92.2% in the 3rd quarter. AlphaQuest LLC now owns 32,123 shares of the medical technology company’s stock valued at $262,000 after acquiring an additional 15,413 shares during the last quarter. Federated Hermes Inc. lifted its stake in shares of Inogen by 0.8% in the 3rd quarter. Federated Hermes Inc. now owns 426,864 shares of the medical technology company’s stock valued at $3,487,000 after acquiring an additional 3,544 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Inogen by 203.9% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 586,159 shares of the medical technology company’s stock valued at $3,622,000 after acquiring an additional 393,310 shares during the last quarter. 89.94% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on INGN. Freedom Capital upgraded Inogen to a “strong-buy” rating in a research note on Tuesday, April 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Inogen in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Inogen currently has an average rating of “Moderate Buy” and an average target price of $14.00.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.